Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) shares saw unusually-high trading volume on Friday . Approximately 416,429 shares changed hands during mid-day trading, an increase of 0% from the previous session’s volume of 414,646 shares.The stock last traded at $15.27 and had previously closed at $14.71.

A number of brokerages have recently commented on BLCM. Jefferies Group cut their price target on Bellicum Pharmacueticals from $35.00 to $19.00 and set a “buy” rating for the company in a report on Tuesday, March 15th. Zacks Investment Research lowered Bellicum Pharmacueticals from a “hold” rating to a “sell” rating in a report on Thursday, March 17th. Piper Jaffray Cos. reiterated a “buy” rating and set a $33.00 price target (down from $45.00) on shares of Bellicum Pharmacueticals in a report on Monday, March 14th. Finally, SunTrust Banks Inc. began coverage on Bellicum Pharmacueticals in a report on Thursday, June 2nd. They set a “buy” rating and a $20.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $28.00.

The stock’s 50 day moving average price is $12.53 and its 200-day moving average price is $11.60. The stock’s market cap is $403.68 million.

Bellicum Pharmacueticals (NASDAQ:BLCM) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.51) by $0.07. On average, equities analysts predict that Bellicum Pharmacueticals Inc. will post ($2.22) EPS for the current year.

In related news, VP Ken Moseley sold 15,000 shares of the stock in a transaction dated Thursday, June 2nd. The stock was sold at an average price of $13.00, for a total transaction of $195,000.00. Following the completion of the transaction, the vice president now directly owns 15,196 shares in the company, valued at $197,548. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CTO Kevin M. Slawin sold 55,000 shares of the stock in a transaction dated Friday, April 22nd. The stock was sold at an average price of $11.43, for a total value of $628,650.00. Following the transaction, the chief technology officer now owns 159,206 shares of the company’s stock, valued at $1,819,724.58. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Bellicum Pharmacueticals stock. Morgan Stanley boosted its position in Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, Holdings Channel reports. The fund owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned approximately 1.61% of Bellicum Pharmacueticals worth $8,653,000 as of its most recent filing with the SEC.

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system in real time.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.